Oyster Point Pharma to Participate in the 41st Annual Cowen Healthcare Conference

PRINCETON, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. OYST, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 41^st Annual Cowen Healthcare Conference on Tuesday, March 2, 2021, at 11:10 a.m. ET, and host investor meetings.

To access the live webcast, please visit the "Investors and News" section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.

About Oyster Point Pharma, Inc.

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit. OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any use in any country. The safety and efficacy of OC-01 (varenicline) nasal spray have not previously been established.

Investor Contact: 

Tim McCarthy 

LifeSci Advisors, LLC 

(212) 915-2564 

investors@oysterpointrx.com

Media Contact: 

Sheryl Seapy

W2O Group 

(213) 262-9390 

sseapy@w2ogroup.com